Incyte is now ranked among the top 25 undervalued stocks included in the Nasdaq Composite Index. A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company. Valuation methodology provided by Stockcalc (see below).
Stocks in this market cap category are held primarily for capital appreciation and/or dividends. Inclusion in a major index means a company ranks among the largest in their market. This also implies stability by-way of institutional support for the stock by index funds.
More about Incyte
All data provided as-at market close June 08, 2023. The list is sorted by stocks with the greatest percentage difference between valuation and price. Incyte Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary therapeutics. Its product JAKAFI, a JAK1 and JAK2 inhibitor is used for treatment of patients with intermediate or high risk myelofibrosis. Incyte is listed under INCY on the NASDAQ.
Stockcalc
StockCalc is a Canadian fintech company specializing in fundamental valuations for North American stocks and ETFs. StockCalc valuations (https://www.stockcalc.com/Resources) can help determine if a stock is undervalued. StockCalc's Weighted Average Valuation (WAV) is based on a proprietary calculation using model and analyst inputs, including: Discounted Cash Flow (DCF), Price & Other Comparables, Multiples, Adjusted Book Value (ABV) and Analyst Consensus
Artificial intelligence at Report on Business
Artificial Intelligence at Report on Business Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.